SEC Filing Document

Company: BIOVENTRIX, INC.
Ticker: 
CIK: 1283259
Filing Type: S-1
Document Type: S-1
Date Filed: 2026-02-12
Accession Number: 0001493152-26-006407
Exchange: 
SIC Code: 3841
SIC Description: Surgical & Medical Instruments & Apparatus
URL: https://www.sec.gov/Archives/edgar/data/1283259/000149315226006407/forms-1.htm

Chunk 58 of 83
Word Count: 1498
Character Count: 9371

Document Content:

Shares of common stock Beneficially Owned After Offering Name and Address of Beneficial Owner (1) Number (7) (8) Percentage (2) Number Percentage (3) Executive Officers and Directors Steve Chartier 110,530 0.81 % * Ori Ben-Yehuda 110,000 0.81 % * David Richmond 4,098,586 (4) 30.01 % [●] % Mark Ravich 1,010,714 (6) 7.40 % [●] % Rishi Puri – William T. Abraham – All directors and executive officers as a group (6 individuals) 5,329,830 39.02 % % 5% or Greater Stockholders Michael Taglich 1,390,549 (5) 10.18 % [●] % Less than 1%. (1) Except as otherwise indicated, the business address of our directors and executive officers is 120 Forbes Blvd., Suite 125, Mansfield, MA (2) Based on 13,657,839 shares of common stock outstanding as of the date of this prospectus. (3) Based on [●] shares of common stock outstanding immediately after the offering assuming no exercise of the underwriters’ over-allotment option.

(4)	Includes
(a) 194,000 shares of common stock directly held by Mr. Richmond (including 25,665 shares of common stock from Second RSA
Grant 2024 and 18,335 shares of common stock from Second RSA Grant 2025), (b) 2,524,268 shares of common stock, comprised
of 148,400 Series A shares convertible into common stock and $2,375,868 Secured Convertible Notes held by RBI BioVentrix LLC
convertible into 2,375,868 shares of common stock, (c) 461,223 shares of common stock comprised of 385,832 shares of common
stock and 75,391 Series A shares convertible into common stock held by RBI Opportunities Fund LLC, (d) 355,595 shares of common stock
comprised of 311,668 shares of common stock and 43,927 Series A shares convertible into common stock held by RBI BV Private Investment,
(e) 277,590 common shares comprised of 226,025 shares of common stock and 51,565 Series A shares convertible into common stock held
by RBI Private Investment III LLC, (f) 255,740 shares, comprised of 215,077 shares of common stock and 40,663 Series A shares convertible
into common stock held by RBI Opportunities Fund II LLC, (g) 11,199 shares comprised of 8,300 shares of common stock and 2,899 Series
A shares convertible into common stock held by David Richmond & Stephanie Richmond, (h) 9,486 shares comprised of 8,123 shares
of common stock and 1,363 Series A shares convertible into common stock held by RBI Private Investment I LLC, and (i) 9,485 shares,
comprised of 8,123 shares of common stock and 1,362 Series A shares convertible into common stock held by Richmond Brothers Inc.
Mr. Richmond is the Manager and has voting and investment control of RBI BioVentrix LLC, RBI Opportunities Fund LLC, RBI BioVentrix,
LLC, RBI BV Private Investment, RBI Private Investment III LLC, RBI Opportunities Fund II LLC, David Richmond & Stephanie Richmond,
RBI Private Investment I LLC, and Richmond Brothers Inc, (collectively, the “Richmond Entities”). Mr. Richmond disclaims
any beneficial ownership of the securities held by the Richmond Entities, other than to the extent of any pecuniary interest he may
have therein, directly or indirectly.

(5)	Includes
(a) 381,952 shares, comprised of 119,902 shares of common stock and 262,050 Series A shares convertible into common stock held directly
by Mr. Taglich, (b) 103,654 shares of common stock held by Taglich Brothers Inc., (c) 84,408 shares of common stock held by Michael
N. Taglich & Claudia Taglich, (d) 177 shares of common stock held by Claudia Ruggiero Taglich, (e) 3,179 shares of common stock
held by Michael Taglich C/F Amanda Taglich UTMA NY, (f) 3,179 shares of common stock held by Michael Taglich C/F Lucy Taglich UTMA
NY, (g) 3,179 shares of common stock held by Michael Taglich C/F Stella Taglich UTMA NY, (h) 130,142 shares of common stock held
by Michael N. Taglich Keogh Account, (i) 3,179 shares of common stock held by Michael Taglich TTEE Hope A Taglich Supplemental Needs
Trust UAD 8/23/17, and (j) 677,500 Series A shares convertible into common stock held by Bioventrix investors LLC. Mr. Taglich is
the President of Taglich Brothers Inc., Michael N. Taglich Keogh Account, Michael Taglich TTEE Hope A Taglich Supplemental Needs
Trust UAD 8/23/17, and Bioventrix investors LLC and has voting and investment control over the shares held by Michael N. Taglich
& Claudia Taglich, Claudia Ruggiero Taglich, Michael Taglich C/F Amanda Taglich UTMA NY, Michael Taglich C/F Lucy Taglich UTMA
NY, and Michael Taglich C/F Stella Taglich UTMA NY (collectively, the “Taglich Entities”). Mr. Taglich disclaims any
beneficial ownership of the securities held by the Taglich Entities, other than to the extent of any pecuniary interest he may have
therein, directly or indirectly.

(6)	Includes
(a) 165,000 common shares directly held by Mr. Ravich (including 57,750 common shares from Second RSA Grant 2024 and 41,250
common shares from Second RSA Grant 2025), (b) 10,000 common shares comprised of 10,000 Series A shares held by Mark Ravich
Irrevocable Trust, (c) 227,631 common shares comprised of 79,880 Series A shares, $131,892 Secured Convertible Notes,
and $15,859 Series A-1 Secured Convertible Notes held by Mark Ravich Revocable Trust, (d) 370,001 common shares comprised
of 93,590 common shares, 10,000 Series A shares, and $266,411 Secured Convertible Notes held by Mark Ravich TTEE Mark Ravich
Irrevocable Trust UAD 11/05/18, (e) 87,938 common shares held by Mark H. Ravich TTEE Revocable Trust of Mark H. Ravich UAD 10/08/19,
(f) 70,680 common shares comprised of 5,000 Series A shares and $65,680 Secured Convertible Notes held by Norman and
Sally Ravich Family Trust, (g) 40,261 common shares held by Mark Ravich TTEE Cindy Libman Irrevocable Trust UAD 11/05/18, (h) 17,482
common shares held by Mark H. Ravich TTEE Norman & Sally Ravich Family Trust UAD 12/24/92, (i) 8,123 common shares held by Alexander
Coleman Ravich 1991 Irrevocable Trust, (j) 8,123 common shares held by Alyssa Danielle Ravich 1991 Irrevocable Trust, and (k) 5,475
common shares held by Ilyne Ravich. Mr. Ravich is the Trustee and has voting and investment control of Mark Ravich Irrevocable Trust,
Revocable Trust of Mark Ravich, Mark Ravich TTEE Mark Ravich Irrevocable Trust UAD 11/05/18, Mark H. Ravich TTEE Revocable Trust
of Mark H. Ravich UAD 10/08/19, Norman and Sally Ravich Family Trust, Mark Ravich TTEE Cindy Libman Irrevocable Trust UAD 11/05/18,
Mark H. Ravich TTEE Norman & Sally Ravich Family Trust UAD 12/24/92, Alexander Coleman Ravich 1991 Irrevocable Trust, and Alyssa
Danielle Ravich 1991 Irrevocable Trust (collectively, the “Ravich Entities”). Mr. Ravich disclaims any beneficial ownership
of the securities held by the Ravich Entities, other than to the extent of any pecuniary interest he may have therein, directly or
indirectly.

(7)	For
note conversions into shares assumes that interest accrues through November 30, 2025 on the
March 2024 Through August 2024 Series A Secured Convertible Note Financing and the October
2024 Through September 2025 Series A-1 Secured Convertible Note Financing.

(8)	The
Secured Convertible Notes convert into our common stock subject to an initial public offering
generating $7.5 million of gross proceeds. We have assumed the initial public offering price
is at least $10.00 per share, generating gross proceeds of $[   ]. Each
$1.00 decrease in the assumed initial public offering price of $
per share (the midpoint of the estimated price range set forth on the cover page of this
prospectus) below $10.00 per share would increase the number of shares issued upon
the conversion by approximately $        , assuming the
number of shares, as set forth on the cover page of this prospectus, remains the same and
after deducting underwriting discounts and estimated offering expenses payable by us.

CERTAIN
RELATIONSHIPS AND RELATED PARTY TRANSACTIONS

During
the period from January 1, 2023 to the date of this prospectus, we have entered into or participated in the following transactions with
related persons:

On January 2, 2026, the
Company granted 90,000 restricted stock awards to the three independent members of the Company’s board of directors, valued at
$1.14 per share, of which 3,750 will vest each month through December 2027.

On October 1, 2025,
the Company granted 422,500 stock options at an exercise price of $1.14 per share. The options vest 105,625 after one year
and, thereafter, 8,802 of the option shares shall vest at the end of each full month over thirty-six (36) consecutive months.
Certain of the Company’s executive officers and members of the board were granted 265,000 of the 422,500 stock options
granted.

On January 15, 2025, Mr. Chartier,
our Co-Chief Executive Officer and President, was granted 220,000 stock options at an exercise price of $1.00 per share. The option
shares vest 55,000 after one year and, thereafter, 4,583 of the option shares shall vest at the end of each full month
over thirty-six (36) consecutive months.

On January 1, 2025,
Mr. Richmond, our Co-Chief Executive Officer and Chief Financial Officer was granted 191,000 stock options at an exercise price of
$1.00 per share. The option shares vest 47,750 after one year and, thereafter, 3,979 of the option shares shall vest at the end of
each full month over thirty-six (36) consecutive months.

In March 2024, officers
and directors received 348,000 shares of restricted stock awards, 232,000 shares valued at $0.80 per share vested immediately.